New leukemia drug tested for safety in japanese patients
NCT ID NCT06649006
Summary
This small, early-stage study tested the safety and side effects of an intravenous drug called blinatumomab in six Japanese adults with a specific type of newly diagnosed blood cancer (B-ALL). The goal was to see how the drug is processed by the body and to check for any serious reactions in this patient group. Participants had already achieved initial remission with standard chemotherapy before receiving the study drug.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Akita University Hospital
Akita, Akita, 010-8543, Japan
-
Fukushima Medical University Hospital
Fukushima, Fukushima, 960-1295, Japan
-
Kanazawa University Hospital
Kanazawa, Ishikawa-ken, 920-8641, Japan
-
Kurume University Hospital
Kurume-shi, Fukuoka, 830-0011, Japan
-
Kyushu University Hospital
Fukuoka, Fukuoka, 812-8582, Japan
-
Yamagata University Hospital
Yamagata, Yamagata, 990-9585, Japan
Conditions
Explore the condition pages connected to this study.